Inclusion Criteria:

Stage A: Patient:

- aged > 18 years.

- with a histological proven diagnosis of epithelial cancer of the ovary, the fallopian
tube or extra-ovarian papillary serous tumors.

- with asymptomatic disease in progression detected by increase of CA 125 levels
according to GCIG criteria during systematic follow-up, with or without measurable
lesions.

- with disease in progression > 6 months after a first or second line including a
platinum derivative. Patients should have received previously a taxane derivative.

- Adequate bone marrow, renal and hepatic function defined as: . WBC > 3.0 x 109/L or
Neutrophils (ANC) > 1,5 x 109/L; Platelets > 100 x 109/L; Hemoglobin > 6 mmol/L (10,0
mg/dL); Bilirubin < 2 x upper normal limit of normal range; Estimated glomerular
filtration rate > 50 ml/mn according to Cockroft-Gault formula.

- with ECOG performance status = 0 or 1.

- with a life expectancy of at least 16 weeks

- who have given their signed and written informed consent to participate in the trial
after fully understanding the implication and constraints of the protocol.

Stage B: Patients

- aged > 18 years.

- with a histological proven diagnosis of epithelial cancer of the ovary, the fallopian
tube or extra-ovarian papillary serous tumors.

- with disease in progression > 6 months after a first or second line including a
platinum derivative. patients should have received previously a taxane derivative.

- Measurable disease by RECIST or evaluable disease by GCIG (CA-125).

- Patients included in stage A with disease in progression under lenalidomide could be
eligible in phase B if they did not experience unacceptable toxicity under
lenalidomide in stage A. Patients should stop lenalidomide for 7 days before entry in
stage B (7 days wash out).

- Adequate bone marrow, renal and hepatic function defined as: . WBC > 3.0 x 109/L or
Neutrophils (ANC) > 1,5 x 109/L; Platelets > 100 x 109/L; Hemoglobin > 6 mmol/L (10,0
mg/dL); Bilirubin < 2 x upper normal limit of normal range; Estimated glomerular
filtration rate > 50 ml/mn according to Cockroft-Gault formula.

- with LVEF under normal range

- with ECOG performance status = 0 or 1.

- with a life expectancy of at least 16 weeks.

- who have given their signed and written informed consent to participate in the trial
after fully understanding the implication and constraints of the protocol.

Exclusion Criteria:

- Ovarian tumors of low malignant potential (borderline tumors).

- Non-epithelial ovarian or mixed epithelial/non epithelial tumors (e.g. mixed
Mullerian tumors).

- Patients with a prior diagnosis of any malignancy not cured by surgery alone less
than 5 years before study entry (except in situ carcinoma of the cervix or adequately
treated basal cell carcinoma of the skin).

- Patients who have received previous radiotherapy.

- Presence of symptomatic brain metastases.

- Patients with a history of seizure disorder or central nervous system disorders;
pre-existing motor or sensory neurologic pathology or symptoms > NCI-CTC grade 1.

- History of congestive heart failure (NYHA Classification > 2, even if medically
controlled. History of clinical and electrocardiographically documented myocardial
infarction within the last 6 months. History of atrial or ventricular arrhythmias (≥
LOWN II).

- Thrombosis or anti-thrombosis treatment within 6 months.

- History of visceral bleeding, gastrointestinal ulcer in 6 months.

- Obstructive or sub-occlusive disease.

- Patients with severe active infection.

- Concurrent severe medical problems unrelated to malignancy which would significantly
limit full compliance with the study or expose the patient to extreme risk or
decreased life expectancy.

- Fertile women not using adequate contraceptive methods, or who are pregnant or breast
feeding.

- Histories of allergy or sentimentality known about the similar chemical compounds in
the carboplatine, either in the doxorubicine liposomale pégylée, or in one of the
constituents of the lenalidomide.

- Patient having developed a knotty erythema characterized by a rash with desquamation
during grip(taking) of thalidomide or a medicine similaire.

- Previous administration of lenalidomide.

- Seropositivity known about the virus of the human immunodeficiency (HIV), or
pathology bound to the syndrome of acquired immunodeficiency (AIDS) or hepatitis
activates type A, B or C.

- Administration of other simultaneous chemotherapeutic drugs, or hormonal therapy, or
simultaneous radiotherapy during the study treatment period (hormone replacement
therapy is allowed as are steroid antiemetics).

- Dementia or significantly altered mental status that would prohibit the understanding
and giving of informed consent.